Actively Recruiting
POlycythemia, Proteins and ErYthropoiesis
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-04-01
400
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Erythropoiesis encompasses all the stages and mechanisms involved in the production of red blood cells, or erythrocytes, under the control of a large number of regulatory agents, most often proteins. Among these proteins, erythropoietin and interleukin-3 play a major role. Similarly, proteins involved in iron metabolism (erythroferrone, hepcidin, ferroportin, transferrin, ferritin) influence erythrocyte production more or less directly. The regulation of erythropoiesis is a fine, complex mechanism involving a large number of players, not only through the stimulation of hypoxia pathways to control erythropoietin synthesis, but also through the availability of iron, an essential element for erythropoiesis. Excessive erythrocyte production can lead to polycythemia, the causes of which are varied, primary or secondary, acquired or constitutional. The aim of this work is the descriptive study (quantitative and/or qualitative) of the various proteins involved in the regulation of erythropoiesis in patients with polycythemia. These proteins will be measured in the plasma of patients obtained after blood sampling or bloodletting (bloodletting being the most common treatment for polyglobulic patients) and will be compared with the proteins of patients without polycythemia.
CONDITIONS
Official Title
POlycythemia, Proteins and ErYthropoiesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Persons who have given their non-opposition
- Patients with polycythemia having hemoglobin value > 16 g/dl for females or > 16.5 g/dl for males
- Patients with a well-identified cause of polycythemia, either primary (such as polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation) or secondary (including cardio-respiratory pathologies, renal pathologies like post-transplant or polycystic kidney disease, metabolic pathologies, tumors like leiomyoma or pheochromocytoma, and constitutional mutations such as hyperaffine hemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL)
- Control patients with similar pathologies to polycythemia patients but without polycythemia, having hemoglobin value < 16 g/dl for females and < 16.5 g/dl for males
You will not qualify if you...
- Persons subject to a measure of legal protection (guardianship, tutorship)
- Persons subject to a court order
- Pregnant, parturient or nursing women
- Persons incapable of expressing consent
- Minors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Dijon Bourgogne
Dijon, France, 21000
Actively Recruiting
Research Team
F
François GIRODON
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here